Stock in the Spotlight: Earth Science Tech Inc (ETST), AURORA CANNABIS IN COM NPV (ACBFF), Cannabis Science Inc (CBIS)

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -2.45% and closed at $1.99, with the total traded volume of 17,778.00 shares. During last trade its minimum price was $1.90 and it gained its highest price of $2.09 and has a total of 81.42 million outstanding shares.

Earth Science Tech, Inc., a biotechnology company, focuses on delivering nutraceuticals, bioceuticals, and dietary supplements in the areas of health, wellness, sports, and alternative medicine worldwide. It focuses on non-prescription nutritional and dietary supplements for the treatment of chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging, and overall wellness. The company also provides consulting services to the athletic facilities industry. Its marketing services include direct marketing, search engine optimization, public relations, email marketing, social media marketing, and development of referral programs. In addition, Earth Science Tech, Inc. retails health and wellness brands, as well as sports nutrition and dietary supplement products; and stocks and sells high grade cannabidiol rich hemp oil and products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in April 2014. The company was incorporated in 2010 and is headquartered in Boca Raton, Florida.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) showing dropped of -0.64% and closed at $1.70, after gaining total volume of 344,055.00 shares. Its earnings per share (EPS) are -$0.05 and it has total market capitalization of $475.70 million and a total of 275.93 million outstanding shares.

AURORA CANNABIS IN COM NPV (ACBFF) on January 26, 2017 announced that it has entered into an amending agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (collectively, the “Underwriters”) to increase the size of its previously announced private placement offering. Pursuant to the revised terms of the offering, the Underwriters have agreed to purchase, on a bought deal private placement basis, 26,670,000 units of the Company (the “Units”), at a price of $2.25 per Unit (the “Offering Price”) for aggregate gross proceeds to Aurora of $60,007,500.00 (the “Offering”).

The Company has granted the Underwriters an option (the “Underwriters’ Option”), exercisable in whole or in part up to 48 hours prior to the closing of the Offering, to purchase up to 6,667,500 additional Units of the Company at the Offering Price.  If the underwriters’ Option is exercised in full the aggregate gross proceeds of the Offering will be $75,009,375.

Each Unit will be comprised of one common share of the Company (a “Common Share”) and half of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share (a “Warrant Share”) for a period of two years following the closing date of the Offering at an exercise price of $3.00 per Warrant Share, subject to adjustment in certain events. The Warrants will be subject to a forced exercise provision if the Company’s daily volume weighted average share price on the TSX Venture Exchange (or such other stock exchange the Company may be trading on) is greater than $4.50 for 10 consecutive trading days following the date that is four months and one day following the closing of the Offering. Net proceeds from the Offering will be used primarily towards the Company’s strategic growth initiatives including its planned facility expansion, and for general working capital purposes.

Cannabis Science Inc (OTCMKTS:CBIS) increased 1.27% closed at $0.0840 and traded with total volume of 12.53 million shares, while the average trading remained 34.21 million shares. During last trade its minimum price was $0.08 and it gained the highest price of $0.08. Its market capitalization was $189.22 million.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phyto cannabinoid-based pharmaceutical products primarily in the United States. The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market; and collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug. The company also has a collaborative research agreement with Dana Farber/Harvard Cancer Center to explore and develop cannabinoid medicines to fight cancer. Cannabis Science, Inc. is based in Colorado Springs, Colorado. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.